These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

635 related items for PubMed ID: 30786783

  • 1. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
    Berardi A, Siddiqui MK, Treharne C, Harty G, Wong SL.
    Curr Med Res Opin; 2019 Aug; 35(8):1371-1378. PubMed ID: 30786783
    [Abstract] [Full Text] [Related]

  • 2. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis.
    Siddiqui MK, Khurana IS, Budhia S, Hettle R, Harty G, Wong SL.
    Curr Med Res Opin; 2018 Aug; 34(8):1361-1371. PubMed ID: 29149804
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R, Harty G, Wong SL.
    J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
    [Abstract] [Full Text] [Related]

  • 4. Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Śladowska K, Kawalec P, Holko P, Osiecka O.
    Neurol Sci; 2022 Sep; 43(9):5479-5500. PubMed ID: 35713731
    [Abstract] [Full Text] [Related]

  • 5. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
    Gonzalez-Lorenzo M, Ridley B, Minozzi S, Del Giovane C, Peryer G, Piggott T, Foschi M, Filippini G, Tramacere I, Baldin E, Nonino F.
    Cochrane Database Syst Rev; 2024 Jan 04; 1(1):CD011381. PubMed ID: 38174776
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
    Pinheiro B, Guerreiro R, Costa J, Miguel LS.
    J Med Econ; 2020 May 04; 23(5):484-491. PubMed ID: 31951777
    [Abstract] [Full Text] [Related]

  • 7. Comparative effectiveness and safety of ozanimod versus other oral DMTs in relapsing-remitting multiple sclerosis: a synthesis of matching-adjusted indirect comparisons.
    Paul D, Swallow E, Patterson-Lomba O, Branchcomb T, N'Dri L, Gomez-Lievano A, Liu J, Dua A, McGinley M.
    Ther Adv Neurol Disord; 2024 May 04; 17():17562864241237856. PubMed ID: 38855023
    [Abstract] [Full Text] [Related]

  • 8. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
    Huisman E, Papadimitropoulou K, Jarrett J, Bending M, Firth Z, Allen F, Adlard N.
    BMJ Open; 2017 Mar 10; 7(3):e013430. PubMed ID: 28283486
    [Abstract] [Full Text] [Related]

  • 9. Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.
    Cohan S, Kumar J, Arndorfer S, Zhu X, Zivkovic M, Tencer T.
    CNS Drugs; 2021 Jul 10; 35(7):795-804. PubMed ID: 33847901
    [Abstract] [Full Text] [Related]

  • 10. Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study.
    Brownlee WJ, Haghikia A, Hayward B, Waser N, Kayaniyil S, Khan Z, Duncan J, Millar S, Harty GT.
    Mult Scler Relat Disord; 2023 Aug 10; 76():104791. PubMed ID: 37343465
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.
    Roos I, Sharmin S, Malpas C, Ozakbas S, Lechner-Scott J, Hodgkinson S, Alroughani R, Eichau Madueño S, Boz C, van der Walt A, Butzkueven H, Buzzard K, Skibina O, Foschi M, Grand'Maison F, John N, Grammond P, Terzi M, Prévost J, Barnett M, Laureys G, Van Hijfte L, Luis Sanchez-Menoyo J, Blanco Y, Oh J, McCombe P, Ramo Tello C, Soysal A, Prat A, Duquette P, Yamout BI, Khoury S, van Pesch V, Macdonell R, José Sá M, Slee M, Kuhle J, Maimone D, Spitaleri D, Willekens B, Asmi AA, Tallantyre E, Robertson NP, Coles A, L Brown JW, Kalincik T.
    Mult Scler; 2024 Aug 10; 30(9):1163-1175. PubMed ID: 39087208
    [Abstract] [Full Text] [Related]

  • 12. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.
    Fogarty E, Schmitz S, Tubridy N, Walsh C, Barry M.
    Mult Scler Relat Disord; 2016 Sep 10; 9():23-30. PubMed ID: 27645339
    [Abstract] [Full Text] [Related]

  • 13. Cladribine vs other drugs in MS: Merging randomized trial with real-life data.
    Signori A, Saccà F, Lanzillo R, Maniscalco GT, Signoriello E, Repice AM, Annovazzi P, Baroncini D, Clerico M, Binello E, Cerqua R, Mataluni G, Perini P, Bonavita S, Lavorgna L, Zarbo IR, Laroni A, Pareja-Gutierrez L, La Gioia S, Frigeni B, Barcella V, Frau J, Cocco E, Fenu G, Clerici VT, Sartori A, Rasia S, Cordioli C, Stromillo ML, Di Sapio A, Pontecorvo S, Grasso R, Barone S, Barrilà C, Russo CV, Esposito S, Ippolito D, Landi D, Visconti A, Sormani MP.
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov 10; 7(6):. PubMed ID: 32801167
    [Abstract] [Full Text] [Related]

  • 14. Systematic review and network meta-analysis (NMA) for cladribine tablets in achieving sustained disability improvement (SDI) in multiple sclerosis.
    Piasecka-Stryczyńska K, Kaczyński Ł, Rolka M, Homa M, Staśkiewicz W, Paczwa P, Wójcik R, Kaczor MP, Rejdak K.
    Neurol Neurochir Pol; 2022 Nov 10; 56(6):480-489. PubMed ID: 36421066
    [Abstract] [Full Text] [Related]

  • 15. Quantifying the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis in the United Kingdom: A time and motion study.
    Rog D, Brownlee W, Carod-Artal FJ, Kalra S, Barker N, Lowndes C, Pendlebury J, Leclerc S, Amin A, Ashton L, Evans H, De Cock E.
    Mult Scler Relat Disord; 2024 Feb 10; 82():105380. PubMed ID: 38183696
    [Abstract] [Full Text] [Related]

  • 16. Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands.
    Michels RE, de Fransesco M, Mahajan K, Hengstman GJD, Schiffers KMH, Budhia S, Harty G, Krol M.
    Appl Health Econ Health Policy; 2019 Dec 10; 17(6):857-873. PubMed ID: 31444659
    [Abstract] [Full Text] [Related]

  • 17. Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Lambe T, Duarte R, Mahon J, Nevitt S, Greenhalgh J, Boland A, Beale S, Kotas E, McEntee J, Pomeroy I.
    Pharmacoeconomics; 2019 Mar 10; 37(3):345-357. PubMed ID: 30328051
    [Abstract] [Full Text] [Related]

  • 18. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
    Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, Laureys G, Kalincik T, Van Der Walt A, Yamout B, Lechner-Scott J, Soysal A, Kuhle J, Sanchez-Menoyo JL, Blanco Morgado Y, Spitaleri D, van Pesch V, Horakova D, Ampapa R, Patti F, Macdonell R, Al-Asmi A, Gerlach O, Oh J, Altintas A, Tundia N, Wong SL, Butzkueven H.
    Mult Scler; 2023 Feb 10; 29(2):221-235. PubMed ID: 36433775
    [Abstract] [Full Text] [Related]

  • 19. Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis.
    Mankinen P, Lundström T, Soini E, Sumelahti ML, Ruutiainen J, Niskala U, Järvinen E.
    Adv Ther; 2020 Feb 10; 37(2):800-818. PubMed ID: 31873868
    [Abstract] [Full Text] [Related]

  • 20. Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study.
    Alroughani R, Al-Hashel J, Ahmed SF.
    Clin Neurol Neurosurg; 2024 May 10; 240():108249. PubMed ID: 38513425
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.